|1.||Senter, Peter D: 4 articles (09/2009 - 07/2003)|
|2.||Alley, Stephen C: 4 articles (09/2009 - 06/2006)|
|3.||Olson, William C: 3 articles (01/2014 - 04/2006)|
|4.||Carter, Paul J: 3 articles (04/2009 - 06/2006)|
|5.||Gerber, Hans-Peter: 3 articles (04/2009 - 08/2008)|
|6.||Meyer, Damon L: 3 articles (11/2006 - 07/2003)|
|7.||Maderna, Andreas: 2 articles (06/2015 - 12/2014)|
|8.||Leverett, Carolyn A: 2 articles (06/2015 - 12/2014)|
|9.||Ramakrishnan, Vanitha: 2 articles (07/2013 - 10/2003)|
|10.||Coleman, Robert L: 2 articles (02/2013 - 09/2009)|
06/01/2015 - "The main focus will be to describe structural changes made to the auristatin peptide and their resulting biological activities in tumor cell proliferation assays. "
12/26/2014 - "This modification of the peptide structure is unprecedented and led to analogues with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs. "
05/01/2014 - "A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate."
02/15/2014 - "TF-011-MMAE (HuMax-TF-ADC) was the most potent ADC, and the dominant mechanism of action in vivo was auristatin-mediated tumor cell killing. "
02/01/2013 - "We aimed to evaluate the safety profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate composed of the cytotoxic drug auristatin (toxin) linked to a human anti-EphA2 monoclonal antibody (1C1), in patients with solid tumors relapsed/refractory to standard therapy. "
01/01/2014 - "We have included brief discussions of the approved agents, where they are in trials to extend their initial approved activity (a common practice once an agent is approved), and have also included an extensive discussion of the use of auristatin derivatives as warheads, plus an area that has rarely been covered, the use of marine-derived agents to ameliorate the pain from cancers in humans, and to act as an adjuvant in immunological therapies. "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2014 - "PSMA-targeted ADCs have been developed using auristatin and maytansinoid drugs, and each ADC has undergone extensive preclinical testing and has completed phase 1 testing in men with advanced prostate cancer. "
04/15/2006 - "The findings support development of PSMA antibody-auristatin conjugates for therapy of prostate cancer."
|4.||Melanoma (Melanoma, Malignant)
08/24/2010 - "Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75."
07/01/2003 - "We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to CD30 on hematological malignancies). "
|1.||Surface Antigens (Surface Antigen)
|7.||Immunoglobulin G (IgG)
|1.||Transcutaneous Electric Nerve Stimulation (TENS)